Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7242265 | 0.93 | HPGD (0.73) | HPGDALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL7238451 | 0.88 | HPGD (0.64) | HPGDALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL13468069 | 0.88 | ALDH1A1 (0.67) | HPGDALDH1A1SMN1; SMN2POLBKMT2A | |
| SCHEMBL192942 | 0.88 | HPGD (0.77) | HPGDALDH1A1SMN1; SMN2POLBKMT2A | |
| SCHEMBL29978605 | 0.88 | HPGD (0.77) | HPGDALDH1A1SMN1; SMN2POLBTSHR | |
| SCHEMBL6271671 | 0.88 | HPGD (0.77) | HPGDALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL12504031 | 0.88 | HPGD (0.77) | HPGDALDH1A1SMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL22660182 | 0.86 | HPGD (0.75) | HPGDALDH1A1SMN1; SMN2POLBTSHR | |
| SCHEMBL5745620 | 0.86 | HPGD (0.71) | HPGDALDH1A1SMN1; SMN2POLBTSHR | |
| SCHEMBL2560313 | 0.85 | HPGD (0.73) | HPGDALDH1A1SMN1; SMN2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2064187-A2 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008024497-A2 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024497-A2 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-6664271-B1 | Amide, carbamate and uredo derivatives of 3-piperidine-carboxylic acid or ester; protecting against infection by such as escherichia coli and/or actinobacillus pleuropneumoniae | ELI LILLY AND COMPANY | 2003-12-16 | — | — | US | disclosed |
| WO-2000071519-A2 | IMMUNOPOTENTIATOR AGENTS | ELI LILLY AND COMPANY (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HPGD 71/4885ALDH1A1 78/4885SMN1; SMN2 3320/4885 |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | HPGD 1821/4885ALDH1A1 772/4885SMN1; SMN2 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.